The head of SK-Pharmaceuticals, Erken Zhakatay, held a meeting with representatives of the domestic pharmaceutical company Khimpharm JSC.
Khimpharm JSC was represented by the director for hospital business and interaction with government agencies, Aigul Isenova, and the manager for work with government agencies, Didar Doskhodzhaeva.
During the meeting, Aigul Isenova shared the company’s latest achievements. In particular, she noted that Khimpharm JSC with the SANTO Member of Polpharma Group trademark is a leading pharmaceutical enterprise in Kazakhstan with a plant in the city of Shymkent, with a portfolio of more than 240 generic drugs in 12 pharmacotherapeutic groups.
Chimpharm is the only domestic manufacturer in Kazakhstan of injection solutions and powder dosage forms packaged in glass ampoules and bottles.
The pharmaceutical company has its own R&D laboratory and a wide portfolio of drugs exported to Uzbekistan, Russia, Mongolia, Turkmenistan, Tajikistan, and Kyrgyzstan.
As of today, 9 long-term contracts for the supply of 186 types of medicines have been concluded between SK-Pharmaceuticals and Khimpharm JSC.
“We plan to modernize our Research Testing Center and increase the staff there by 20-25% to implement new projects, and today we are building a new laboratory that will comply with the international GMP standard,” noted Aigul Isenova.
In turn, Chairman of the Board of SK-Pharmaceuticals Erken Zhakatay expressed interest in mutual cooperation and assured that the Unified Distributor is ready to become a dialogue platform for the medical, scientific and business communities in order to solve systemic problems and develop the industry.
At the end of the meeting, the parties agreed to consolidate joint efforts to achieve more effective indicators for the development of the country's pharmaceutical industry.
